14 Gastric Polyp Guidelines From 2026: What New AGA Recommendations Mean for Your Digestive Health

Gastric polyps—small growths in the stomach lining—are found in approximately 6% of all upper endoscopy procedures, yet most patients and even many healthcare providers remain unaware of their varying risks and management options. The American Gastroenterological Association (AGA) just released groundbreaking clinical practice updates in February 2026 that dramatically clarify how different types of gastric polyps should be detected, classified, treated, and monitored.

These new guidelines are particularly important because while most gastric polyps are benign, certain types—especially adenomatous polyps—carry significant risks for progression to gastric cancer if left undetected or improperly managed. Understanding these latest recommendations could literally save your life.

What Are Gastric Polyps and Why Do They Matter?

Gastric polyps are raised epithelial lesions that project from the stomach's mucosal or submucosal tissue into the stomach lumen. According to the 2026 AGA Clinical Practice Update published in Clinical Gastroenterology and Hepatology, these lesions encompass several distinct histologic subtypes, each with unique characteristics and malignant potential:

• Fundic gland polyps (FGPs): Found in 37-77% of all gastric polyps, most common in middle-aged women
• Gastric hyperplastic polyps (GHPs): Second most common type, representing 17-42% of cases
• Gastric adenomas (GAs): Less common at 0.5-1%, but carry the highest cancer risk
• Pyloric gland adenomas and oxyntic gland adenomas: Rare variants with specific locations
• Gastric neuroendocrine tumors (G-NETs): Associated with chronic gastritis and hypergastrinemia

Perhaps most surprisingly, the new guidelines emphasize that different types of gastric polyps may coexist in the same person—a finding that requires clinicians to carefully evaluate not just individual polyps but the entire gastric landscape during endoscopic examination.

The Hidden Danger: Not All Polyps Are Equal

One of the most critical insights from the 2026 AGA update is understanding the varying malignant potential across different polyp types. Fundic gland polyps, which are the most frequently encountered, have less than a 1% risk of malignancy in sporadic cases. However, when associated with familial adenomatous polyposis (FAP), up to 40% may contain dysplasia.

Hyperplastic polyps present a more nuanced picture. While their overall malignant transformation rate ranges from 0.6% to 8%, research published in StatPearls identified specific high-risk features:

• Size greater than 25 mm (approximately 1 inch)
• Presence of intestinal metaplasia in adjacent tissue
• Dysplasia in surrounding stomach lining

These findings mean that a simple "watch and wait" approach is inappropriate for many hyperplastic polyps that previously would have been monitored conservatively.

Gastric adenomas represent thehighest risk category. As stated in the AGA guidelines, these lesions are direct precursors to gastric adenocarcinoma and require complete resection with systematic endoscopic follow-up. Current data shows that 1.3% of people who have had an adenoma removed will eventually develop gastric cancer—underscoring the importance of lifelong surveillance after initial removal.

The H. pylori Connection That Doctors Often Miss

Perhaps the most actionable finding in the new guidelines involves the bacterium Helicobacter pylori. The AGA now provides a clear best practice recommendation: All patients with adenomatous or hyperplastic gastric polyps should be tested and treated if positive for H. pylori infection.

This recommendation is backed by compelling evidence. According to data cited in the guidelines, H. pylori infection is associated with up to 89% of non-cardia gastric cancers globally. Importantly, eradication of this bacterium correlates with a 32% pooled relative risk reduction for related gastric cancer—a number that translates to real lives saved.

The connection between H. pylori and polyps extends beyond mere correlation. Research from the NCBI Bookshelf explains that H. pylori increases serum gastrin levels, which can lead to atrophic gastritis and subsequent enterochromaffin-like cell proliferation—creating a perfect storm for hyperplastic polyp formation. Perhaps most encouragingly, hyperplastic polyps often regress within one year after successful H. pylori eradication, assuming no reinfection occurs.

Proton Pump Inhibitors: When to Continue and When to Question Use

For millions of Americans taking proton pump inhibitors (PPIs) for acid reflux or ulcer prevention, the new guidelines offer important reassurance. The AGA explicitly states that patients using PPIs for valid clinical reasons do not need to discontinue these medications when fundic gland polyps are found.

However, this comes with an important caveat. Research has documented a clear association between long-term PPI use and fundic gland polyp development. A prospective cohort study demonstrated a 17-fold increased relative risk for fundic gland polyps over 10 years of continuous PPI use. Another analysis of 186 individuals found that more than 5 years of PPI therapy significantly increased the incidence of these lesions.

The guidelines recommend that when fundic gland polyps larger than 5-10 mm are detected in patients on chronic PPIs, clinicians should:

1. Document the polyp findings with high-definition imaging and photographs
2. Continue therapeutic PPI use when medically justified
3. Schedule follow-up endoscopy in 1 year if lesions are significant

For sporadic fundic gland polyps without dysplasia, no further surveillance is typically needed after initial characterization—saving patients from unnecessary repeat procedures.

Advanced Imaging: Why Standard Endoscopy May No Longer Be Enough

The 2026 AGA update emphasizes that basic white-light endoscopy alone is insufficient for comprehensive gastric polyp evaluation. The guidelines now recommend complete inspection with high-definition white-light AND enhanced imaging techniques such as virtual chromoendoscopy.

Virtual chromoendoscopy—including technologies like narrow-band imaging (NBI), blue laser imaging, and linked color imaging—allows endoscopists to better visualize the vascular patterns and surface architecture that distinguish benign fundic gland polyps from potentially pre-cancerous adenomas in real-time.

Endoscopists performing polyp evaluations should also document:

• The specific location of each polyp within stomach regions (antrum, corpus, fundus)
• Size measurements in millimeters
• Surface characteristics (smooth vs. irregular, ulceration, bleeding points)
• Surrounding mucosal abnormalities such as atrophy or intestinal metaplasia
• Multiple photographic images for future comparison

This comprehensive documentation supports accurate surveillance planning and helps detect subtle changes that might signal progression toward malignancy between procedures.

The Surveillance Timeline That Could Save Your Life

Surveillance recommendations in the 2026 guidelines are meticulously tailored to individual risk factors, polyp type, and histopathology findings:

For adenomatous polyps:

• Complete resection is mandatory
• Follow-up endoscopy at 1 year after removal
• Ongoing surveillance every 3-5 years if no recurrence

For hyperplastic polyps with H. pylori:

• Initial antibiotic therapy to eradicate the bacteria
• Repeat endoscopy in 3-6 months to confirm eradication and assess regression

For dysplastic lesions (the highest risk category):

• Low-grade dysplasia, completely resected: surveillance at 1 year
• High-grade dysplasia, completely resected: surveillance at 6 months
• Biopsy-only or incomplete resection with high-grade dysplasia: follow-up within 3 months

For fundic gland polyps associated with FAP:

• Annual endoscopic surveillance is mandatory
• Rigorous biopsy sampling of all suspicious lesions
• Consider colonoscopy to rule out synchronous colorectal polyposis

The AGA guidelines also specify that when surrounding mucosa shows gastric intestinal metaplasia or atrophic gastritis, ongoing endoscopic surveillance should continue even after the polyp itself has been successfully removed—because the field defect remains a risk factor for future cancer development.

Red Flags: When Polyps Signal Genetic Cancer Syndromes

While most gastric polyps occur sporadically, certain patterns should trigger investigation for hereditary cancer syndromes with dramatically increased risks:

Familial Adenomatous Polyposis (FAP):

• Up to 88% of FAP patients develop fundic gland polyps
• Gastric adenomas found in 10% in Western populations, up to 36-50% in Asia
• Documented cases of gastric cancer as young as age 16

Peutz-Jeghers Syndrome:

• Characteristic lip and skin pigmentation alongside gastrointestinal polyps
• Average age of malignant transformation around 30 years
• Yearly screening recommended beginning in childhood for those already diagnosed

Cowden Syndrome:

• Associated PTEN tumor suppressor gene mutations
• Significant risks for breast, thyroid, endometrial, and gastric cancers
• Hamartomatous polyps that closely mimic hyperplastic polyps histologically

These genetic conditions account for a small percentage of total gastric polyp cases but carry profound implications for patient management, family screening, and cancer prevention strategies.

Treatment Approaches: From Simple Polypectomy to Endoscopic Submucosal Dissection

The technical recommendations in the 2026 update reflect significant advances in endoscopic therapeutic capabilities:

Traditional techniques:

• Hot and cold snare polypectomy for pedunculated lesions
• Biopsy forceps for very small (<5mm) lesions when resection isn't feasible
• Hot biopsy techniques combining removal with coagulation

Advanced endoscopic methods:

• Endoscopic mucosal resection (EMR) for larger adenomas and high-risk polyps
• Endoscopic submucosal dissection (ESD) for complete en-bloc removal of suspicious lesions

For GIST greater than 2 cm, the American College of Gastroenterology specifically recommends either EMR or ESD. Neuroendocrine tumors generally require surgical resection if larger than 1 cm or demonstrating aggressive histologic features.

The choice between techniques depends on polyp size, location, suspected invasion depth, and available endoscopic expertise—emphasizing that not all gastroenterologists have equivalent training in advanced therapeutic procedures.

The Bottom Line: What Patients Should Know

The essential message for consumers from these guidelines is straightforward: gastric polyps warrant attention but rarely represent immediate emergencies. Finding a polyp during endoscopy doesn't automatically mean you face cancer—the risk varies dramatically based on histology, size, and accompanying features.

Key takeaways include:

1. Always ask your gastroenterologist about testing for H. pylori if any polyp is found
2. Understand which type of polyp(s) were discovered and what that means for future surveillance
3. Never discard biopsy results—keep records showing histology for comparison with future procedures
4. If taking PPIs long-term, ask whether periodic endoscopic monitoring makes sense
5. Family history of polyps or gastric cancer warrants earlier and more frequent surveillance

The American Gastroenterological Association's 2026 Clinical Practice Update on Gastric Polyp Management represents a significant advance in digestive health care—translating complex research into clear, actionable guidance that can help prevent gastric cancer before it develops. By understanding these guidelines, patients can have more informed discussions with their healthcare providers about whether they need surveillance, what risks their specific findings represent, and when to seek second opinions for comprehensive management.

---

Medical Disclaimer: This article is for informational purposes only and should not replace consultation with qualified healthcare professionals. The guidance herein reflects current medical literature but individual patient care decisions require personalized clinical assessment by your treating physician. Always discuss any concerning symptoms or polyp findings directly with a gastroenterologist who has access to your complete medical history, endoscopic images, and pathology reports.

---

References

1. Buchner AM, Huang RJ, Lauwers GY, El-Serag HB. AGA Clinical Practice Update on Management of Gastric Polyps: Expert Review. Clin Gastroenterol Hepatol. 2026 Apr;24(4):893-905. doi: 10.1016/j.cgh.2026.01.007. Published Feb 19, 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41711625/

2. American Gastroenterological Association. 14 tips for managing gastric polyps. Gastro.org. March 30, 2026. URL: https://gastro.org/news/14-tips-for-managing-gastric-polyps/

3. Arteaga CD, Wadhwa R. Gastric Polyp. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Updated October 9, 2024. URL: https://www.ncbi.nlm.nih.gov/books/NBK560704/